Information Provided By:
Fly News Breaks for April 25, 2018
BFRA
Apr 25, 2018 | 08:51 EDT
Lake Street analyst Bruce Jackson started Biofrontera with a Buy rating and $19 price target. This is the year all the pieces come together for Ameluz, Biofrontera's novel photodynamic drug therapy for pre-cancerous skin lesions, Jackson tells investors in a research note. He believes his 2019 revenue forecast of $42.6M forecast could be conservative if Ameluz can expand into the cryoablation market in addition to capturing market share from an existing PDT competitor.
News For BFRA From the Last 2 Days
There are no results for your query BFRA
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.